Jupiter Asset Management Ltd. Has $532,000 Holdings in AbbVie Inc. $ABBV

Jupiter Asset Management Ltd. decreased its stake in AbbVie Inc. (NYSE:ABBV) by 99.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,297 shares of the company’s stock after selling 290,801 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in AbbVie were worth $532,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Woodley Farra Manion Portfolio Management Inc. boosted its stake in shares of AbbVie by 358.1% in the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 14,746 shares of the company’s stock valued at $3,414,000 after purchasing an additional 11,527 shares in the last quarter. D Orazio & Associates Inc. lifted its holdings in AbbVie by 7.3% during the 3rd quarter. D Orazio & Associates Inc. now owns 5,068 shares of the company’s stock valued at $1,173,000 after purchasing an additional 346 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in AbbVie by 44.1% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 487,025 shares of the company’s stock valued at $111,854,000 after buying an additional 148,970 shares in the last quarter. Fiera Capital Corp grew its stake in AbbVie by 51.3% during the third quarter. Fiera Capital Corp now owns 164,617 shares of the company’s stock worth $38,115,000 after buying an additional 55,807 shares during the last quarter. Finally, Midland Wealth Advisors LLC increased its holdings in shares of AbbVie by 7.1% during the third quarter. Midland Wealth Advisors LLC now owns 15,196 shares of the company’s stock worth $3,518,000 after buying an additional 1,009 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

Analysts Set New Price Targets

A number of research firms have recently issued reports on ABBV. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. JPMorgan Chase & Co. lifted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Barclays started coverage on AbbVie in a research note on Thursday. They issued an “overweight” rating and a $275.00 price objective on the stock. Citigroup lowered their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $252.79.

AbbVie Stock Performance

NYSE ABBV opened at $224.94 on Monday. The stock has a market capitalization of $397.56 billion, a P/E ratio of 95.31, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a fifty day moving average of $224.04 and a 200-day moving average of $222.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s payout ratio is presently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.